


# Convalescent Plasma therapy for COVID-19:

## A systematic review and meta-analysis on Randomized Controlled Trials


### Supplementary material

**Supplementary Figure S1.** 28-day mortality, by adjustment




**Figure S1.** Forest plot describing the association between convalescent plasma treatment and 28-day mortality. Apart from the overall analysis, the sub-analysis on adjustment type is presented.

**Supplementary Figure S2.** 28-day mortality, by multicenter status




**Figure S2.** Forest plot describing the association between convalescent plasma treatment and 28-day mortality. Apart from the overall analysis, the sub-analysis on multicenter status is presented.

**Supplementary Figure S3.** 28-day mortality, by blinding status



**Figure S3.** Forest plot describing the association between convalescent plasma treatment and 28-day mortality. Apart from the overall analysis, the sub-analysis on blinding status is presented.


**Supplementary Figure S4.** 28-day mortality, by geographic region



**Figure S4.** Forest plot describing the association between convalescent plasma treatment and 28-day mortality. Apart from the overall analysis, the sub-analysis by geographic region is presented.




**Supplementary Figure S5.** 28-day mortality, by titer




**Figure S5.** Forest plot describing the association between convalescent plasma treatment and 28-day mortality. Apart from the overall analysis, the sub-analysis by titer is presented.

# Supplementary Figure S6. 28-day hospitalization, by adjustment




**Figure S6.** Forest plot describing the association between convalescent plasma treatment and 28-day hospitalization. Apart from the overall analysis, the sub-analysis by adjustment is presented.

**Supplementary Figure S7.** 28-day hospitalization, by multicenter status




**Figure S7.** Forest plot describing the association between convalescent plasma treatment and 28-day hospitalization. Apart from the overall analysis, the sub-analysis by multicenter status is presented.

**Supplementary Figure S8.** 28-day hospitalization, by blinding status



**Figure S8.** Forest plot describing the association between convalescent plasma treatment and 28-day hospitalization. Apart from the overall analysis, the sub-analysis by blinding status is presented.


**Supplementary Figure S9.** 28-day hospitalization, by geographic region



**Figure S9.** Forest plot describing the association between convalescent plasma treatment and 28-day hospitalization. Apart from the overall analysis, the sub-analysis by geographic region is presented.




**Supplementary Figure S10.** 28-day hospitalization, by titer




**Figure S10.** Forest plot describing the association between convalescent plasma treatment and 28-day hospitalization. Apart from the overall analysis, the sub-analysis by titer is presented.

**Supplementary Figure S11.** 28-day hospital discharge, by adjustment




**Figure S11.** Forest plot describing the association between convalescent plasma treatment and 28-day hospital discharge. Apart from the overall analysis, the sub-analysis by adjustment is presented.

**Supplementary Figure S12.** 28-day hospital discharge, by multicenter status




**Figure S12.** Forest plot describing the association between convalescent plasma treatment and 28-day hospital discharge. Apart from the overall analysis, the sub-analysis by multicenter is presented.

**Supplementary Figure S13.** 28-day hospital discharge, by blinding status



**Figure S13.** Forest plot describing the association between convalescent plasma treatment and 28-day hospital discharge. Apart from the overall analysis, the sub-analysis by blinding status is presented.


**Supplementary Figure S14.** 28-day hospital discharge, by geographic region



**Figure S14.** Forest plot describing the association between convalescent plasma treatment and 28-day hospital discharge. Apart from the overall analysis, the sub-analysis by geographic region is presented.




**Supplementary Figure S15.** 28-day hospital discharge, by titer




**Figure S15.** Forest plot describing the association between convalescent plasma treatment and 28-day hospital discharge. Apart from the overall analysis, the sub-analysis by titer is presented.

**Supplementary Figure S16.** 28-day ICU-related outcomes, by adjustment




**Figure S16.** Forest plot describing the association between convalescent plasma treatment and 28-day ICU related outcomes. Apart from the overall analysis, the sub-analysis by adjustment is presented.

**Supplementary Figure S17.** 28-day ICU-related outcomes, by multicenter status




**Figure S17.** Forest plot describing the association between convalescent plasma treatment and 28-day ICU related outcomes. Apart from the overall analysis, the sub-analysis by multicenter status is presented.

**Supplementary Figure S18.** 28-day ICU-related outcomes, by adjustment



**Figure S18.** Forest plot describing the association between convalescent plasma treatment and 28-day ICU related outcomes. Apart from the overall analysis, the sub-analysis by blinding status is presented.


**Supplementary Figure S19.** 28-day ICU-related outcomes, by geographic region



**Figure S19.** Forest plot describing the association between convalescent plasma treatment and 28-day ICU related outcomes. Apart from the overall analysis, the sub-analysis by geographic region is presented.




**Supplementary Figure S20.** 28-day ICU-related outcomes, by ICU status




**Figure S20.** Forest plot describing the association between convalescent plasma treatment and 28-day ICU related outcomes. Apart from the overall analysis, the sub-analysis by ICU status is presented.

**Supplementary Figure S21.** 28-day ICU-related outcomes, by titer




**Figure S21.** Forest plot describing the association between convalescent plasma treatment and 28-day ICU related outcomes. Apart from the overall analysis, the sub-analysis by titer is presented.

**Supplementary Figure S22.** 28-day score-related outcomes, by adjustment




**Figure S22.** Forest plot describing the association between convalescent plasma treatment and 28-day score-related outcomes. Apart from the overall analysis, the sub-analysis by adjustment is presented.

**Supplementary Figure S23.** 28-day score-related outcomes, by multicenter status



**Figure S23.** Forest plot describing the association between convalescent plasma treatment and 28-day score-related outcomes. Apart from the overall analysis, the sub-analysis by multicenter status is presented.


**Supplementary Figure S24.** 28-day score-related outcomes, by blinding status



**Figure S24.** Forest plot describing the association between convalescent plasma treatment and 28-day score-related outcomes. Apart from the overall analysis, the sub-analysis by blinding status is presented.




**Supplementary Figure S25.** 28-day score-related outcomes, by geographic region




**Figure S25.** Forest plot describing the association between convalescent plasma treatment and 28-day score-related outcomes. Apart from the overall analysis, the sub-analysis by geographic region is presented.

**Supplementary Figure S26.** 28-day score-related outcomes, by titer




**Figure S26.** Forest plot describing the association between convalescent plasma treatment and 28-day score-related outcomes. Apart from the overall analysis, the sub-analysis by titer is presented.

**Supplementary Figure S27.** 14-day mortality, by adjustment




**Figure S27.** Forest plot describing the association between convalescent plasma treatment and 14-day mortality. Apart from the overall analysis, the sub-analysis by adjustment is presented.

**Supplementary Figure S28.** 14-day mortality, by multicenter status




**Figure S28.** Forest plot describing the association between convalescent plasma treatment and 14-day mortality. Apart from the overall analysis, the sub-analysis by multicenter status is presented.

**Supplementary Figure S29.** 14-day mortality, by blinding status




**Figure S29.** Forest plot describing the association between convalescent plasma treatment and 14-day mortality. Apart from the overall analysis, the sub-analysis by blinding status is presented.

**Supplementary Figure S30.** 14-day mortality, by geographic region



**Figure S30.** Forest plot describing the association between convalescent plasma treatment and 14-day mortality. Apart from the overall analysis, the sub-analysis by geographic region is presented.

**Supplementary Figure S31.** 14-day mortality, by titer



**Figure S31.** Forest plot describing the association between convalescent plasma treatment and 14-day mortality. Apart from the overall analysis, the sub-analysis titer is presented.

Supplementary Figure S32. 14-day hospital discharge, by adjustment





Figure S32. Forest plot describing the association between convalescent plasma treatment and 14-day hospital discharge. Apart from the overall analysis, the sub-analysis by adjustment is presented.




**Supplementary Figure S33.** 14-day hospital discharge, by multicenter status




**Figure S33.** Forest plot describing the association between convalescent plasma treatment and 14-day hospital discharge. Apart from the overall analysis, the sub-analysis by multicenter status is presented.

**Supplementary Figure S34.** 14-day hospital discharge, by blinding status



**Figure S34.** Forest plot describing the association between convalescent plasma treatment and 14-day hospital discharge. Apart from the overall analysis, the sub-analysis by blinding status is presented.

**Supplementary Figure S35.** 14-day hospital discharge, by multicenter status



**Figure S35.** Forest plot describing the association between convalescent plasma treatment and 14-day hospital discharge. Apart from the overall analysis, the sub-analysis by geographic region is presented.

Supplementary Figure S36. 14-day hospital discharge, by titer





Figure S36. Forest plot describing the association between convalescent plasma treatment and 14-day hospital discharge. Apart from the overall analysis, the sub-analysis by titer is presented.

**Supplementary Figure S37.** Funnel plot, portraying publication bias for 28-day mortality



**Supplementary Figure S38.** Funnel plot, portraying publication bias for 28-day ICU-related outcomes

